세계의 역형성 성상세포종 시장 보고서(2025년)

Anaplastic astrocytoma is a rare and malignant brain tumor that originates from astrocytes, which are the supportive cells in the nervous system. This condition can lead to neurological symptoms such as headaches, seizures, behavioral changes, and motor deficits, and is typically managed through a combination of surgical procedures, radiation therapy, and chemotherapy.

Anaplastic astrocytoma is categorized into four main grades such as Grade I, Grade II, Grade III, and Grade IV. Grade I anaplastic astrocytoma tumors are the least aggressive and considered benign. They are typically treated with surgical excision, routine monitoring, and follow-up procedures. Treatment options for anaplastic astrocytoma also include surgery, chemotherapy, and radiation, which are further classified into pre-registration and clinical trial phases. These treatments are administered by medical facilities such as hospitals and clinics, and the medications can be obtained from retail pharmacies and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The anaplastic astrocytoma market research report is one of a series of new reports from The Business Research Company that provides anaplastic astrocytoma market statistics, including anaplastic astrocytoma industry global market size, regional shares, competitors with an anaplastic astrocytoma market share, detailed anaplastic astrocytoma market segments, market trends and opportunities and any further data you may need to thrive in the anaplastic astrocytoma industry. This anaplastic astrocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $0.44 billion in 2024 to $0.46 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to growing adoption of targeted therapies, patient advocacy and awareness, clinical trial expansion, healthcare policy and funding, government initiatives.

The anaplastic astrocytoma market size is expected to see strong growth in the next few years. It will grow to $0.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing research and development activities, growing demand for personalized medicine, growing investments, increasing awareness of the disease, increasing stress and depression. Major trends in the forecast period include advancements in neurosurgery, radiation therapy advancements, clinical trials and research, adoption of telemedicine and remote monitoring technologies, advancements in imaging, biotechnology and drug development.

The forecast of 6.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. neuro-oncology by inflating prices of temozolomide capsules and tumor-treating field devices developed in Israel and Italy, resulting in delayed glioma treatment and higher neuro-oncology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anaplastic astrocytoma market is anticipated to experience growth due to the increasing occurrence of both primary malignant and non-malignant brain tumors. Brain tumors are abnormal growths within the brain that can be categorized as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying levels of aggressiveness and potential to spread. Anaplastic astrocytoma treatment involves the removal of the tumor and surrounding affected tissue while preserving brain function. For instance, as reported by the American Society of Clinical Oncology (ASCO), a non-profit organization based in the United States, it is estimated that around 24,810 adults in the U.S. will receive diagnoses of primary cancerous brain and spinal cord tumors in March 2023, with 14,280 cases in men and 10,530 in women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors is poised to be a driving factor for the growth of the anaplastic astrocytoma market in the future.

The anticipated growth in the anaplastic astrocytoma market is expected to be driven by government funding for brain cancer research. Government funding involves financial support provided by government entities at various levels (federal, state, or local) to support organizations, initiatives, projects, programs, or individuals. Numerous government authorities are actively funding research related to brain cancer treatments, including anaplastic astrocytoma. For example, in June 2023, the Australian Department of Health and Aged Care initiated The Australian Brain Cancer Mission, allocating $136.66 million to support brain cancer research. The mission aims to double survival rates and enhance the quality of life for brain cancer patients, including those with anaplastic astrocytoma. As a result, government funding for brain cancer research is a key driver for the anaplastic astrocytoma market.

Prominent companies in the anaplastic astrocytoma market are actively engaged in pioneering novel treatment options with the aim of enhancing effectiveness, reducing side effects, and ultimately improving patient outcomes. For example, in June 2022, the U.S. Food and Drug Administration, a federal agency based in the United States, granted accelerated approval for an innovative treatment combination featuring the oral medications dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors characterized by the BRAF V600E mutation. This approval applies to both adult and pediatric patients with high- and low-grade gliomas that have shown progression following prior treatments. The BRAF V600E mutation is prevalent in various types of gliomas, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas. The decision to grant approval was based on clinical trials of the Tafinlar-Mekinist combination therapy, which demonstrated tumor shrinkage benefits for both adult and pediatric glioma patients. High-grade glioma patients exhibited a 33% response rate, low-grade glioma patients showed a 50% response rate, and pediatric glioma patients demonstrated a 25% response rate.

Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma's Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.

North America was the largest region in the anaplastic astrocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anaplastic astrocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anaplastic astrocytoma market consists of revenues earned by entities by providing targeted therapies, genetic testing and biomarker analysis, clinical trials and healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anaplastic astrocytoma market also includes sales of surgical equipment, imaging devices and radiation therapy equipment that are used in providing anaplastic astrocytoma treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anaplastic Astrocytoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anaplastic astrocytoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anaplastic astrocytoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anaplastic astrocytoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Grade I; Grade II; Grade III; Grade IV
• 2) By Treatment Type: Surgery; Chemotherapy; Radiation
• 3) By Treatment Phase: Pre-Registration Phase; Clinical Trial Phase
• 4) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Grade I: Pilocytic Astrocytoma
• 2) By Grade II: Diffuse Astrocytoma; Oligodendroglioma
• 3) By Grade III: Anaplastic Astrocytoma; Anaplastic Oligodendroglioma
• 4) By Grade IV: Glioblastoma Multiforme (GBM); Primary Glioblastoma; Secondary Glioblastoma
• Companies Mentioned: Pfizer Inc.; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Eisai Co. Ltd; Boehringer Ingelheim International GmbH; Perrigo Company Plc; Ipsen SA; Genentech Inc; Cipla Limited; Novocure Ltd.; Celon Laboratories Limited; Avid Bioservices Inc.; EirGen Pharma Ltd.; Monteris Medical Corporation; GLS Pharma Pvt. Ltd.; Tocagen Inc.; Pharma's Almanac; Inovio Pharmaceuticals Inc.; Isarna Therapeutics GmbH; Actiza Pharmaceutical Private Limited; Celldex Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anaplastic Astrocytoma Market Characteristics

3. Anaplastic Astrocytoma Market Trends And Strategies

4. Anaplastic Astrocytoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Anaplastic Astrocytoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anaplastic Astrocytoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anaplastic Astrocytoma Market Growth Rate Analysis
• 5.4. Global Anaplastic Astrocytoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anaplastic Astrocytoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anaplastic Astrocytoma Total Addressable Market (TAM)

6. Anaplastic Astrocytoma Market Segmentation

• 6.1. Global Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Grade I
• Grade II
• Grade III
• Grade IV
• 6.2. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Radiation
• 6.3. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Registration Phase
• Clinical Trial Phase
• 6.4. Global Anaplastic Astrocytoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pilocytic Astrocytoma
• 6.6. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diffuse Astrocytoma
• Oligodendroglioma
• 6.7. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• 6.8. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glioblastoma Multiforme (GBM)
• Primary Glioblastoma
• Secondary Glioblastoma

7. Anaplastic Astrocytoma Market Regional And Country Analysis

• 7.1. Global Anaplastic Astrocytoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anaplastic Astrocytoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anaplastic Astrocytoma Market

• 8.1. Asia-Pacific Anaplastic Astrocytoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anaplastic Astrocytoma Market

• 9.1. China Anaplastic Astrocytoma Market Overview
• 9.2. China Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anaplastic Astrocytoma Market

• 10.1. India Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anaplastic Astrocytoma Market

• 11.1. Japan Anaplastic Astrocytoma Market Overview
• 11.2. Japan Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anaplastic Astrocytoma Market

• 12.1. Australia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anaplastic Astrocytoma Market

• 13.1. Indonesia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anaplastic Astrocytoma Market

• 14.1. South Korea Anaplastic Astrocytoma Market Overview
• 14.2. South Korea Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anaplastic Astrocytoma Market

• 15.1. Western Europe Anaplastic Astrocytoma Market Overview
• 15.2. Western Europe Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anaplastic Astrocytoma Market

• 16.1. UK Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anaplastic Astrocytoma Market

• 17.1. Germany Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anaplastic Astrocytoma Market

• 18.1. France Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anaplastic Astrocytoma Market

• 19.1. Italy Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anaplastic Astrocytoma Market

• 20.1. Spain Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anaplastic Astrocytoma Market

• 21.1. Eastern Europe Anaplastic Astrocytoma Market Overview
• 21.2. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anaplastic Astrocytoma Market

• 22.1. Russia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anaplastic Astrocytoma Market

• 23.1. North America Anaplastic Astrocytoma Market Overview
• 23.2. North America Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anaplastic Astrocytoma Market

• 24.1. USA Anaplastic Astrocytoma Market Overview
• 24.2. USA Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anaplastic Astrocytoma Market

• 25.1. Canada Anaplastic Astrocytoma Market Overview
• 25.2. Canada Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anaplastic Astrocytoma Market

• 26.1. South America Anaplastic Astrocytoma Market Overview
• 26.2. South America Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anaplastic Astrocytoma Market

• 27.1. Brazil Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anaplastic Astrocytoma Market

• 28.1. Middle East Anaplastic Astrocytoma Market Overview
• 28.2. Middle East Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anaplastic Astrocytoma Market

• 29.1. Africa Anaplastic Astrocytoma Market Overview
• 29.2. Africa Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anaplastic Astrocytoma Market Competitive Landscape And Company Profiles

• 30.1. Anaplastic Astrocytoma Market Competitive Landscape
• 30.2. Anaplastic Astrocytoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anaplastic Astrocytoma Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Mylan N.V.
• 31.3. Eisai Co. Ltd
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Perrigo Company Plc
• 31.6. Ipsen SA
• 31.7. Genentech Inc
• 31.8. Cipla Limited
• 31.9. Novocure Ltd.
• 31.10. Celon Laboratories Limited
• 31.11. Avid Bioservices Inc.
• 31.12. EirGen Pharma Ltd.
• 31.13. Monteris Medical Corporation
• 31.14. GLS Pharma Pvt. Ltd.
• 31.15. Tocagen Inc.

32. Global Anaplastic Astrocytoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anaplastic Astrocytoma Market

34. Recent Developments In The Anaplastic Astrocytoma Market

35. Anaplastic Astrocytoma Market High Potential Countries, Segments and Strategies

• 35.1 Anaplastic Astrocytoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anaplastic Astrocytoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anaplastic Astrocytoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer